 Home > Active Ingredient News > Antitumor Therapy > Lancet oncol: Phase 3 | Pembrolizumab as a second and third-line therapy for metastatic triple-negative breast cancer

Lancet oncol: Phase 3 | Pembrolizumab as a second and third-line therapy for metastatic triple-negative breast cancer

 Last Update: 2021-03-20
 Source: Internet
 Author: User

Tags

methotrexate adverse effects

tolterodine 4 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

In the single-group KEYNOTE-012 and KEYNOTE-086 trials, pembrolizumab showed long-lasting anti-tumor activity and controllable safety in metastatic triple-negative breast cancer .

Breast cancer

The KEYNOTE-119 trial is a randomized, open phase 3 trial that recruits patients with diagnosed metastatic triple-negative breast cancer who are at least 18 years old and have an ECOG performance status of 0 or 1 and have previously received first-line treatment for metastatic lesions.

From November 25, 2015 to April 11, 2017, a total of 1098 patients were evaluated, of which 622 (57%) were randomly assigned to the pembrolizumab group (312) or the chemotherapy group (310).

Overall survival

The median follow-up time of pembrolizumab group and chemotherapy group was 31.

The median overall survival of patients with PD-L1 CPS≥10 in the pembrolizumab group and chemotherapy group was 12.

The overall survival of patients with different scores of PD-L1 CPS

For patients with CPS ≥ 1, the median overall survival with pembrolizumab or chemotherapy was 10.

In the total population, the median overall survival of patients in the pembrolizumab group and chemotherapy group was 9.

Adverse reactions

The most common grade 3-4 treatment-related adverse reactions are anemia (pembrolizumab group vs chemotherapy group: 1% vs 3%), leukopenia (<1% vs 5%), and decreased neutrophil count (< 1% vs 10%) and neutropenia (0 vs 13%).

10%) and neutropenia (0 vs 13%).

In summary, the use of pembrolizumab in previously treated metastatic triple-negative breast cancer failed to significantly prolong the overall survival of patients compared with chemotherapy .

Pembrolizumab for previously treated metastatic triple-negative breast cancer failed to significantly prolong the overall survival of patients compared with chemotherapy

Original source:

Eric P Winer, et al.

org/10.
1016/S1470-2045(20)30754-3" target="_blank" rel="noopener">Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.